- Home
- PRHIZ vs SGMT Comparison
PRHIZ vs SGMT Comparison
Compare PRHIZ & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRHIZ
- SGMT
- Stock Information
- Founded
- PRHIZ N/A
- SGMT 2006
- Country
- PRHIZ United States
- SGMT United States
- Employees
- PRHIZ N/A
- SGMT N/A
- Industry
- PRHIZ Property-Casualty Insurers
- SGMT
- Sector
- PRHIZ Finance
- SGMT
- Exchange
- PRHIZ Nasdaq
- SGMT Nasdaq
- Market Cap
- PRHIZ 220.0M
- SGMT 238.7M
- IPO Year
- PRHIZ N/A
- SGMT 2023
- Fundamental
- Price
- PRHIZ $20.40
- SGMT $9.04
- Analyst Decision
- PRHIZ
- SGMT Strong Buy
- Analyst Count
- PRHIZ 0
- SGMT 8
- Target Price
- PRHIZ N/A
- SGMT $26.88
- AVG Volume (30 Days)
- PRHIZ N/A
- SGMT 602.5K
- Earning Date
- PRHIZ N/A
- SGMT 11-12-2025
- Dividend Yield
- PRHIZ N/A
- SGMT N/A
- EPS Growth
- PRHIZ N/A
- SGMT N/A
- EPS
- PRHIZ N/A
- SGMT N/A
- Revenue
- PRHIZ N/A
- SGMT N/A
- Revenue This Year
- PRHIZ N/A
- SGMT N/A
- Revenue Next Year
- PRHIZ N/A
- SGMT N/A
- P/E Ratio
- PRHIZ N/A
- SGMT N/A
- Revenue Growth
- PRHIZ N/A
- SGMT N/A
- 52 Week Low
- PRHIZ N/A
- SGMT $1.73
- 52 Week High
- PRHIZ N/A
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- PRHIZ N/A
- SGMT 66.53
- Support Level
- PRHIZ N/A
- SGMT $7.30
- Resistance Level
- PRHIZ N/A
- SGMT $8.25
- Average True Range (ATR)
- PRHIZ 0.00
- SGMT 0.68
- MACD
- PRHIZ 0.00
- SGMT 0.16
- Stochastic Oscillator
- PRHIZ 0.00
- SGMT 88.31
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.